Summary
Abbott Laboratories (ABT) filed an 8-K on July 9, 2004, to announce its second quarter 2004 results of operations. The filing primarily directs investors to a press release (Exhibit 99.1) for detailed financial information. This press release likely contains key performance metrics and commentary from management regarding the company's performance during the quarter. Notably, the 8-K highlights Abbott's use of non-GAAP financial measures, such as "diluted earnings per common share from continuing operations excluding one-time charges." The company states that these adjusted measures are used internally and provided to investors to offer a clearer view of ongoing business performance by excluding unusual or unpredictable items. Investors are advised to consider these non-GAAP figures alongside, not as a replacement for, GAAP-based financial information.
Key Highlights
- 1Abbott Laboratories announced its second quarter 2004 results of operations on July 9, 2004.
- 2The primary disclosure mechanism for these results is a press release (Exhibit 99.1) furnished with the 8-K.
- 3The filing explicitly mentions the use of non-GAAP financial measures by Abbott.
- 4Key non-GAAP measures cited include diluted earnings per common share and earnings from continuing operations, excluding one-time charges.
- 5Abbott's management believes these non-GAAP measures provide valuable insights into ongoing business performance.
- 6The company cautions investors to view non-GAAP measures as supplemental to, and not substitutes for, GAAP-based financial statements.
- 7Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.